New trial
Phase I trial of ICP-248, novel B-cell receptor modulator in mature B-cell malignancies
- Trial ID
- NCT06351527 on ClinicalTrials.gov
- Cancer type
- Hematological Cancers
- Stage of research
- First-in-human
- Location
- 8 Locations
- Published in
- New in Oncology - July 25, 2025
This study evaluates ICP-248’s safety, tolerability, pharmacokinetics, and preliminary efficacy alone or with CD20-directed antibodies in patients with relapsed/refractory CLL/SLL and mantle cell lymphoma. The trial uses dose-escalation and expansion cohorts—with obinutuzumab or rituximab combinations—to explore ICP-248 as an investigational modulator of B-cell signaling. InnoCare Pharma Inc. sponsors the study.
More in other blood cancers and transplant
-
Trial result · Aug 13, 2026 · NCT04904588
Standard-dose PTCy enables mismatched-donor HCT but carries substantial early infection burden -
Trial result · Aug 6, 2026 · NCT05388123
Low-dose vemurafenib (BRAF V600E inhibitor) + rituximab drives 73% CR with zero grade 3-4 AEs in HCL -
Trial result · Aug 6, 2026 · NCT02113982
Tagraxofusp (CD123-directed cytotoxin) in BPDCN delivers 71%–90% ORR across trials—HSCT bridge drives survival -
New trial · Jun 25, 2026 · NCT07634536
Phase 2 automated VMAT-based TMLI conditioning refines marrow / lymphoid-targeted irradiation for allo-HCT. -
New trial · Jun 25, 2026 · NCT07572006
Phase 1 JNJ-95804306 (no disclosed MOA/target) in relapsed/refractory AML/MDS and CLL/SLL